ArticleFrontiers in oncology2025
Polatuzumab vedotin-R-CHP used for high-risk EBV-negative DLBCL-type post-transplant lymphoproliferative disorder in a long-term kidney transplant recipient: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-transplant lymphoproliferative disorder (PTLD) is a severe life-threatening complication following solid organ transplantation. Among its subtypes, monomorphic PTLD (mPTLD) is the predominant form, most often presenting as diffuse large B-cell lymphoma (DLBCL). Most PTLD is Case description: We report the case of a 57-year-old female who had undergone kidney transplantation 23 years earlier. Routine examination showed elevated serum creatinine and lactate dehydrogenase (LDH) levels, along with tacrolimus concentrations above the therapeutic range. Although asymptomatic, the patient underwent comprehensive evaluation because of the risk of PTLD and graft rejection. Ultrasonography demonstrated multiple masses in the transplanted kidney, and renal biopsy confirmed EBV-negative diffuse large B-cell lymphoma (DLBCL) with a germinal center B-cell (GCB) immunophenotype. An initial clinical response, including partial tumor regression, was observed following a reduction in immunosuppressive therapy and administration of two doses of rituximab. However, the disease progression was confirmed two months later. The patient subsequently underwent six cycles of Pola-R-CHP (polatzumab vedotin, rituximab, cyclophosphamide, adriamycin and dexamethasone; 21-day per cycle). Positron emission tomography/computed tomography (PET/CT) demonstrated regression of the tumor in the transplanted kidney, with a marked reduction in the maximum standardized uptake value (SUVmax). Despite this favorable response, new lesions were detected in the spinal canal of thoracolumbar spine. Conclusion: In this case, Pola-R-CHP achieved a favorable initial response, suggesting a potential role in the management of mPTLD. However, the subsequent central nervous system relapse underscores the need for further studies that incorporating CNS prophylaxis to define its optimal application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.